Families say it's 'completely frustrating' that children with Duchenne Muscular Dystrophy are being denied access to free ...

Dyne anticipates filing a Biologics License Application (BLA) submission for US accelerated approval in early 2026.

John Brandsema, MD, a pediatric neurologist at Children’s Hospital of Philadelphia, speaks with Healio about the latest ...

Michael Rankin, 12, who is desperately waiting for access to the drug, said: “Every second they don’t get this through, one ...

The antimalarial drug mefloquine could help treat genetic diseases such as cystic fibrosis, Duchenne muscular dystrophy, as ...

Dozens of families affected by Duchenne muscular dystrophy (DMD) have urged the Scottish Government to ensure a life-saving ...

Dyne Therapeutics (DYN) announced that the European Commission has granted orphan drug designation for DYNE-251 for the treatment of Duchenne ...

Multidisciplinary coordination across prescribing teams, nursing, laboratory medicine, finance, and infusion centers is crucial for gene therapy delivery in Duchenne muscular dystrophy (DMD).

The orphan drug designation is particularly noteworthy as it can provide Dyne with a range of benefits, including reduced regulatory fees, assistance with clinical protocols, eligibility for research ...

The Jaffa Shriners’ DuBois Area Shrine Club continues to support a wheelchair program that provides essential equipment to ...

The antimalarial drug mefloquine could help treat genetic diseases such as cystic fibrosis, Duchenne muscular dystrophy, as well as some cancers.